Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Development and Validation of a Model to Predict Response to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndromes (MDS).

Mikkael A. Sekeres, MD, MS, Aristoteles Giagounidis, MD, Hagop M. Kantarjian, MD, Ghulam J. Mufti, MD, Pierre Fenaux, Catherine Jia, PhD, Allen S. Yang, MD, PhD, Uwe Platzbecker, MD

Blood (2012) 120 (21): 2801.

https://doi.org/10.1182/blood.V120.21.2801.2801

Published: 2012

Journal Articles

Treatment with the Thrombopoietin (TPO)-Receptor Agonist Romiplostim in Thrombocytopenic Patients (Pts) with Low or Intermediate-1 (int-1) Risk Myelodysplastic Syndrome (MDS): Follow-up AML and Survival Results of a Randomized, Double-Blind, Placebo (PBO)-Controlled Study

Hagop M. Kantarjian, MD, Ghulam J. Mufti, MD, Pierre Fenaux, MD, PhD, Mikkael A. Sekeres, MD, MS, Jeffrey Szer, MBBS, Uwe Platzbecker, MD, Andrea Kuendgen, Gianluca Gaidano, MD, PhD, Wieslaw Wiktor-Jedrzejczak, MD, PhD, John M. Bennett, MD, Anne Meibohm, PhD, Allen S. Yang, MD, PhD, Aristoteles Giagounidis, MD

Blood (2012) 120 (21): 421.

https://doi.org/10.1182/blood.V120.21.421.421

Published: 2012

Journal Articles

Treatment with the Thrombopoietin (TPO)-Receptor Agonist Romiplostim in Thrombocytopenic Patients (Pts) with Low or Intermediate-1 (Int-1) Risk Myelodysplastic Syndrome (MDS): Results of a Randomized, Double-Blind, Placebo(PBO)-Controlled Study

Aristoteles Giagounidis, MD, Ghulam J. Mufti, MD, Hagop M. Kantarjian, Pierre Fenaux, MD, PhD, Mikkael A. Sekeres, MD, MS, Jeffrey Szer, MBBS, FRACP, Andrea Kuendgen, MD, Uwe Platzbecker, MD, Gianluca Gaidano, Wieslaw Jedrzejczak, Kuolung Hu, Allen S. Yang, MD, PhD, Susie Jun

Blood (2011) 118 (21): 117.

https://doi.org/10.1182/blood.V118.21.117.117

Published: 2011

Journal Articles

Update of An Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Romiplostim in Thrombocytopenic Patients with Myelodysplastic Syndromes (MDS)

Pierre Fenaux, MD, PhD, Hagop M. Kantarjian, Petra Muus, MD, PhD, Roger M. Lyons, MD, Richard A. Larson, MD, Mikkael A. Sekeres, MD, MS, Pamela S. Becker, MD, PhD, Catherine Jia, PhD, Allen S. Yang, MD, PhD

Blood (2011) 118 (21): 2772.

https://doi.org/10.1182/blood.V118.21.2772.2772

Published: 2011

Journal Articles

Update from an Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Romiplostim In Thrombocytopenic Patients (Pts) with Myelodysplastic Syndromes (MDS)

Pierre Fenaux, MD, PhD, Hagop Kantarjian, MD, Roger M Lyons, MD, Richard A Larson, MD, Mikkael A Sekeres, MD, MS, Pamela Becker, MD, PhD, Petra Muus, MD, PhD, Catherine Jia, PhD, Allen S Yang, MD, PhD

Blood (2010) 116 (21): 1885.

https://doi.org/10.1182/blood.V116.21.1885.1885

Published: 2010

Journal Articles

Nilotinib-Associated Molecular Responses Achieved in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Patients with a Suboptimal Molecular Response to Imatinib.

Allen S. Yang, MD, PhD, Anand Jillella, MD, Carole B. Miller, MD, Luke P. Akard, MD, Daniel J. DeAngelo, MD, PhD, Stuart L. Goldberg, MD, Denise Williams, MD, Jerald P. Radich, MD

Blood (2009) 114 (22): 2206.

https://doi.org/10.1182/blood.V114.22.2206.2206

Published: 2009

Journal Articles

A Phase I Biological Study of Azacitidine (Vidaza) to Determine the Optimal Biological Dose and Route of Administration.

Ilan Bernstein, MD, Hyang-Min Byun, PhD, Ann Mohrbacher, MD, Dan Douer, MD, Gerry Gorospe, III, RN, BSN, MSN, Allen S. Yang, MD, PhD, Casey L O'Connell, MD

Blood (2009) 114 (22): 1753.

https://doi.org/10.1182/blood.V114.22.1753.1753

Published: 2009

Journal Articles

Genome-Wide DNA Methylation Analysis of Patients with Myelodysplastic Syndrome After Azacitidine Treatment.

Hyang-Min Byun, PhD, Timothy Triche, Jr., M.S., Hyeoung-Joon Kim, MD, PhD, Hee Nam Kim, PhD, Yeo-Kyeoung Kim, MD, Il-Kwon Lee, Ph.D., Jae-Sook Ahn, MD, Je-Jung Lee, MD, Deok-Hwan Yang, MD, Hoon Kook, MD, Tai Ju Hwang, MD, Peter W. Laird, PhD, Daniel Weisenberger, Ph.D., Allen S. Yang, MD, PhD

Blood (2009) 114 (22): 600.

https://doi.org/10.1182/blood.V114.22.600.600

Published: 2009

Journal Articles

Imatinib Meslylate Plasma Levels Predict Compliance in Patients with Chronic Myelogenous Leukemia.

Sunggeun Lee, MD, Courtney Johnson, Yanderi Sandoval, Gerry Gorospe, III, RN, BSN, MSN, Allen S. Yang, MD, PhD, Sikander Ailawadhi, MD

Blood (2009) 114 (22): 4274.

https://doi.org/10.1182/blood.V114.22.4274.4274

Published: 2009

Journal Articles

Phasee I Biological Study of IV and SQ Azacitidine (Vidaza®) to Determine the Optimal Biological Dose in Hematologic Malignancies

Allen S. Yang, MD, PhD, Ann Mohrbacher, MD, Dan Douer, MD, Gerry Gorospe, III, RN, BSN, MSN, Hyang-Min Byun

Blood (2008) 112 (11): 4493.

https://doi.org/10.1182/blood.V112.11.4493.4493

Published: 2008

Journal Articles

Hypermethylation of O 6 -Methylguanine-DNA Methyltransferase (MGMT) Predicts Response to Laromustine (Cloretazine®) in Patients with Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Ilan Bernstein, MD, Francis Giles, MD, Susan O’Brien, MD, Elizabeth Sullivan, MS, Norbert Vey, MD, Allen S. Yang, MD, PhD

Blood (2008) 112 (11): 4463.

https://doi.org/10.1182/blood.V112.11.4463.4463

Published: 2008

Journal Articles

Preclinical Evaluation of Adjuvant Therapy with AMD3100 for Drug Resistant Philadelphia Chromosome Positive and Negative ALL

Enzi Jiang, MD, PhD, Min Yu, MD, PhD, Yao-Te Hsieh, Brian DeLaTorre, Asha Kadavallore, Carlton Scharman, Eugene Park, Allen S. Yang, MD, PhD, Markus Muschen, MD, John Groffen, PhD, Nora Heisterkamp, PhD, Yong-Mi Kim, MD

Blood (2008) 112 (11): 2922.

https://doi.org/10.1182/blood.V112.11.2922.2922

Published: 2008

Journal Articles

Molecular Predictive Markers in Dose Escalation Treatment for Suboptimal Responders to Standard Dose Imatinib in CML

Blood (2008) 112 (11): 3221.

https://doi.org/10.1182/blood.V112.11.3221.3221

Published: 2008

Journal Articles

DNA Methylation Analysis of 807 Genes in Chronic Myeloid Leukemia and Acute Promyelocytic Leukemia.

Hyang-Min Byun, Ph.D., Shahrooz Eshaghian, M.D., Jia Yi Jiang, M.D., Si Ho Choi, M.S., John Soussa, Laleh Ramezani, B.S.C., Dan Douer, M.D., Allen S. Yang, MD, PhD

Blood (2007) 110 (11): 2122.

https://doi.org/10.1182/blood.V110.11.2122.2122

Published: 2007

Journal Articles

Phase I Trial of Fenretinide (4-HPR) Intravenous Emulsion for Hematologic Malignancies.

Ann Mohrbacher, MD, Martin Gutierrez, MD, Anthony J. Murgo, MD, Shivaani Kummar, MD, C. Patrick Reynolds, MD, PhD, Barry J. Maurer, MD, PhD, Susan Groshen, PhD, Lori Vergara, RN, Min H. Kang, Pharm D, Allen S. Yang, MD, PhD

Blood (2007) 110 (11): 2581.

https://doi.org/10.1182/blood.V110.11.2581.2581

Published: 2007

Journal Articles

A Dose Intensified Pediatric-Like Regimen Using Multiple Doses of Intravenous Pegylated Asparaginase in Adults with Newly Diagnosed Acute Lymphoblastic Leukemia.

Dan Douer, MD, Kristy Watkins, RN, Lisa Mark, PA, Ann Mohrbacher, MD, Allen S. Yang, MD, PhD, Prakash N. Tiwari, MD, Vassilos I. Avramis, MD

Blood (2007) 110 (11): 2823.

https://doi.org/10.1182/blood.V110.11.2823.2823

Published: 2007

Journal Articles

Phase I/II Study of the Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor MGCD0103 in Combination with Azacitidine in Patients (pts) with High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML).

Guillermo Garcia-Manero, MD, Allen S. Yang, MD, PhD, Francis Giles, MD, Stefan Faderl, Farhad Ravandi, MD, Jorge Cortes, MD, Willie M. Newsome, RN, Jean-Pierre Issa, MD, Tracy-Ann Patterson, Marja Dubay, Zuomei Li, Hagop Kantarjian, MD, Robert E. Martell, MD

Blood (2006) 108 (11): 1954.

https://doi.org/10.1182/blood.V108.11.1954.1954

Published: 2006

NARROW

Development and Validation of a Model to Predict Response to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndromes (MDS).

Treatment with the Thrombopoietin (TPO)-Receptor Agonist Romiplostim in Thrombocytopenic Patients (Pts) with Low or Intermediate-1 (int-1) Risk Myelodysplastic Syndrome (MDS): Follow-up AML and Survival Results of a Randomized, Double-Blind, Placebo (PBO)-Controlled Study

Treatment with the Thrombopoietin (TPO)-Receptor Agonist Romiplostim in Thrombocytopenic Patients (Pts) with Low or Intermediate-1 (Int-1) Risk Myelodysplastic Syndrome (MDS): Results of a Randomized, Double-Blind, Placebo(PBO)-Controlled Study

Update of An Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Romiplostim in Thrombocytopenic Patients with Myelodysplastic Syndromes (MDS)

Update from an Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Romiplostim In Thrombocytopenic Patients (Pts) with Myelodysplastic Syndromes (MDS)

Nilotinib-Associated Molecular Responses Achieved in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Patients with a Suboptimal Molecular Response to Imatinib.

A Phase I Biological Study of Azacitidine (Vidaza) to Determine the Optimal Biological Dose and Route of Administration.

Genome-Wide DNA Methylation Analysis of Patients with Myelodysplastic Syndrome After Azacitidine Treatment.

Imatinib Meslylate Plasma Levels Predict Compliance in Patients with Chronic Myelogenous Leukemia.

Phasee I Biological Study of IV and SQ Azacitidine (Vidaza®) to Determine the Optimal Biological Dose in Hematologic Malignancies

Hypermethylation of O 6 -Methylguanine-DNA Methyltransferase (MGMT) Predicts Response to Laromustine (Cloretazine®) in Patients with Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Preclinical Evaluation of Adjuvant Therapy with AMD3100 for Drug Resistant Philadelphia Chromosome Positive and Negative ALL

Molecular Predictive Markers in Dose Escalation Treatment for Suboptimal Responders to Standard Dose Imatinib in CML

DNA Methylation Analysis of 807 Genes in Chronic Myeloid Leukemia and Acute Promyelocytic Leukemia.

Phase I Trial of Fenretinide (4-HPR) Intravenous Emulsion for Hematologic Malignancies.

A Dose Intensified Pediatric-Like Regimen Using Multiple Doses of Intravenous Pegylated Asparaginase in Adults with Newly Diagnosed Acute Lymphoblastic Leukemia.

Phase I/II Study of the Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor MGCD0103 in Combination with Azacitidine in Patients (pts) with High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only